IO Biotech appoints David V. Smith to Board of Directors effective March 1, 2022

IO Biotech, Inc.

Smith appointed to Board and Audit Committee effective March 1, 2022.
Annual director retainer $40,000; Audit Committee fee $7,500; receives 28,019 stock options vesting over 3 years.
Smith is former EVP & CFO of Five Prime Therapeutics (acquired by Amgen) with 30+ years biotech leadership.
No related-party transactions or arrangements regarding his selection as director.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David V. Smith

Director

IOBTQ · IO Biotech, Inc.

Effective: 2022-03-01
Filed: March 3, 2022, 6:59 PM ET

On February 28, 2022, the Board of Directors of IO Biotech, Inc. (the “Company”) appointed David V. Smith as a director of the Company, effective as of March 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David V. Smith was appointed as Director at IO Biotech, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 28, 2022, the Board of Directors of IO Biotech, Inc. (the “Company”) appointed David V. Smith as a director of the Company, effective as of March 1, 2022.

View on SEC.gov

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-064390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.